A Phase I/II Trial of the Combination 5-azacitidine and Gemtuzumab Ozogamicin Therapy for Treatment of Relapsed AML
This study will test an experimental combination of the drugs Mylotarg and 5-azacitidine in the hopes of finding a treatment that may be effective against Acute Myeloid Leukemia that has come back after treatment.
Stanford is not currently accepting new patients for this trial. You may want to check clinicaltrials.gov to see if other locations are recruiting.
- drug : 5-Azacitidine
- drug : Gemtuzumab ozogamicin
Phase: Phase 1/Phase 2
Ages Eligible For Study:
- Diagnosis of Relapsed AML - Eastern Cooperative Oncology Group (ECOG) performance status 0-2, and life expectancy > 3 months - ? 18 years old - Previously untreated for current AML relapse - Adequate organ function - Written informed consent